Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection. A combination of these two proteins administered orally conferred improved protection compared to that conferred by either protein administered alone.
Oral administration of antigens offers a number of advantages for the delivery of malaria vaccines. Oral vaccines can be delivered outside a formal clinical setting, without the need for skilled personnel. Eliminating needles from the vaccination process can negate concerns regarding the reuse and disposal of needles and reduce the associated risks, such as the transmission of blood-borne viruses. In addition, oral vaccines appear to offer a relatively straightforward means of combining antigens into a multivalent formulation without the substantial cost and difficulties of reformulating parenteral preparations. Furthermore, if oral vaccination against malaria is feasible, oral vaccines can be further developed based on the use of transgenic plants as bioreactors for the production and possible delivery of vaccine antigens (3) .
Using Plasmodium yoelii merozoite surface proteins 4 and 5 (PyMSP4/5) in an animal model system, it has been previously demonstrated that administration of Escherichia coli-expressed recombinant PyMSP4/5 (EcMSP4/5) in the presence of cholera toxin B subunit (CTB) to mice by gavage induces systemic antibody responses comparable to those achieved with parenteral immunization. The antibodies induced are predominantly immunoglobulin G1 (IgG1) and can protect mice against lethal challenge with P. yoelii (12) . Here we report the oral immunogenicity of a second P. yoelii antigen, the C-terminal 19-kDa fragment of merozoite surface protein 1 (PyMSP1 19 ). We show that protection against lethal P. yoelii infection can be achieved by oral immunization with a recombinant PyMSP1 19 expressed by E. coli. Furthermore, an orally administered combination of recombinant PyMSP4/5 and PyMSP1 19 conferred improved protection compared to that conferred by either protein administered alone.
The C-terminal PyMSP1 19 sequence that corresponds to amino acids 1649 to 1754 and contains the two epidermal growth factor-like domains was expressed in E. coli as a glutathione S-transferase (GST) fusion (9) . This fusion protein, named GST-PyMSP1 19 , was purified from cell extracts by affinity chromatography on glutathione-agarose and eluted with reduced glutathione as described previously (11) . To assess the oral immunogenicity of PyMSP1 19 , 14 female BALB/c mice were administered by gavage an amount of GST-PyMSP1 19 equivalent to 25 g of PyMSP1 19 in the presence of 10 g of CTB. Six immunizations were given, at weeks 0, 1, 2, 3, 6, and 8. Sera were collected at 10 days after the sixth immunization, and the resultant antibodies were measured with an enzymelinked immunosorbent assay as described previously (12) . All mice developed high levels of PyMSP1 19 -specific antibodies, which were comparable to those induced by intraperitoneal immunization with a Saccharomyces cerevisiae-expressed recombinant PyMSP1 19 (data not shown). The predominant isotype of the antibodies was IgG1, with lower IgG2a and IgG2b responses ( Fig. 1) , a pattern identical to that induced by oral immunization with PyMSP4/5 (12) . In order to examine the protective efficacy of the induced antibodies, the immunized mice were challenged at 2 weeks after the sixth immunization with a lethal dose of 10 5 P. yoelii YM parasites as described previously (12) . Eight mice that were immunized with GST and CTB were also challenged under the same protocol. All of these eight mice developed fulminating infections and died between days 5 and 6 postchallenge ( Fig. 2A) . In contrast, 9 of the 14 mice immunized with GST-PyMSP1 19 showed clear evidence of protective immunity and survived the challenge (Fig. 2B ). There was a significant difference in the numbers of surviving mice in the groups (P ϭ 0.0055, as determined by Fisher's exact probability test), and a significant difference was also observed in peak parasitemia levels between the two groups (P ϭ 0.0015, as determined by the Mann-Whitney U test). These data demonstrate that recombinant PyMSP1 19 administered orally in the presence of CTB can induce systemic antibodies and protect a significant proportion of mice against a lethal challenge with P. yoelii.
It is generally believed that an effective subunit malaria vaccine will include multiple protein components; however, there is limited experimental support for this proposition. It has been shown that parenteral immunization with a combination of PyMSP1 19 and PyMSP4/5 induces an improved level of protection compared to that induced by either protein administered alone (8). Burns et al. also showed that a combined formulation of Plasmodium chabaudi MSP1 and apical membrane antigen 1 administered parenterally results in a greater reduction in peak parasitemia levels than that achieved with either antigen alone (1). To examine whether an antigen combination could also be efficacious when administered orally, two additional groups of mice were employed: one group was treated by gavage with 25 g of EcMSP4/5, and the other group was treated by gavage with 25 g of EcMSP4/5 plus an amount of GST-PyMSP1 19 equivalent to 25 g of PyMSP1 19 . As shown in Fig. 2 , immunization with a combination of GSTPyMSP1 19 and EcMSP4/5 had a dramatic effect on the levels of protection. All of the eight immunized mice survived the challenge, with peak parasitemia levels between 0.2 and 55.2%. The differences in peak parasitemia levels between different groups were statistically significant. A P value of 0.0006 (as determined by the Mann-Whitney U test) was found when the comparison was made between the group immunized with Ec-MSP4/5 and the group immunized with the combined antigens, and a P value of 0.036 (as determined by the Mann-Whitney U test) was found when the group immunized with GSTPyMSP1 19 and the group immunized with the combined antigens were compared. The survival rates in the combined-antigen group were improved compared to those in the groups immunized with either antigen alone (100% versus 66.7 and 64.3% for the EcMSP4/5 group and the GST-PyMSP1 19 group, respectively); however, the differences in these survival rates were not significant. The prechallenge antibody responses were analyzed by enzyme-linked immunosorbent assay for both antigens (Fig. 3) . Mice immunized with a combination of EcMSP4/5 and GSTPyMSP1 19 developed high levels of antibodies to both antigens. There was no difference in the antibody responses to EcMSP4/5 between the combined-antigen group and the EcMSP4/5-immunized group (P ϭ 0.1770, as determined by the Mann-Whitney U test); similarly, no difference was observed in the antibody responses to GST-PyMSP1 19 between the combined-antigen group and the GST-PyMSP1 19 -immunized group (P ϭ 0.8112, as determined by the Mann-Whitney U test). The isotype distributions of the PyMSP4/5-specific antibodies were similar in the combined-antigen and EcMSP4/ 5-immunized groups, and the isotype distributions of the PyMSP1 19 -specific antibodies were similar in the combinedantigen and PyMSP1 19 -immunized groups (data not shown). These data demonstrated that oral immunization with a mixture of PyMSP4/5 and PyMSP1 19 neither boosts the antibody reactivity to either antigen nor results in antigen competition. The enhanced protection seemed to be due to an additive effect of the capacity of both antigens to induce a level of protection.
It is generally thought that immunity to P. yoelii is predominantly antibody mediated (4) . It has been shown previously that a significant correlation between PyMSP4/5-specific antibodies and protective efficacy exists (7, 12) . In general, mice with higher antibody responses showed better protection, whereas mice with lower antibody levels showed poor protection or succumbed to the malaria infection. A similar correlation was also observed in this study (data not shown). However, not all mice with high levels of antibodies were protected from parasite infection, indicating that other immune mechanisms also operated to provide the observed protection. Examination of the serum samples from the protected mice after they fully recovered showed that parasite infection neither boosted the specific antibodies to either PyMSP4/5 or PyMSP1 19 nor changed the pattern of isotype profiles (data not shown).
In summary, we have demonstrated that PyMSP1 19 is immunogenic when administered orally and offers protection against challenge with a lethal dose of P. yoelii. PyMSP1 19 is a leading malaria vaccine candidate whose protective efficacy when administered parenterally has been shown in a number of studies (2, 6, 9, 10) . One study showed that intranasal immunization with S. cerevisiae-expressed recombinant PyMSP1 19 induced some degree of protective immunity, suggesting that mucosal delivery of PyMSP1 19 has the potential to protect against malaria via a mechanism similar to that observed following parenteral immunization (5) . This study showed that significant protection can also be induced by oral immunization. Importantly, we have demonstrated that oral immunization with recombinant PyMSP4/5 plus PyMSP1 19 induces antibodies to both antigens and also provides enhanced protection against parasite infection. These data are consistent with those achieved by parenteral immunization (8) and provide a rationale for developing multicomponent oral vaccines.
